Breakthrough Talk: Resveratrol’s Impact on Acute Promyelocytic Leukemia

At the upcoming Cancer Conference 2025, Dr. Minoo Shahidi from the Iran University of Medical Sciences will present her latest findings on the role of Resveratrol (RSV) in reducing the formation of extracellular traps (ETs) in acute promyelocytic leukemia (NB4) cells. ETosis and NETosis, which drive cancer progression, metastasis, and thrombosis, are increasingly seen as potential therapeutic targets. Dr. Shahidi’s study focuses on how Resveratrol, a naturally occurring antioxidant, can help regulate these processes and improve patient outcomes.

The research demonstrates that RSV treatment significantly decreases PAD4 gene expression and lowers TNF-α cytokine release in NB4 cells, both of which are critical in ETosis. Using advanced tools such as fluorescence microscopy, flow cytometry, PCR, and ELISA, her team confirmed RSV’s ability to suppress ETosis. These findings suggest that Resveratrol could potentially reduce bleeding risks and treatment failure in Acute Promyelocytic Leukemia (APL) patients by limiting ETosis-driven complications.

---

🌟 Key Highlights from the Presentation

·         ETosis and NETosis play a major role in cancer spread and thrombosis.

·         Resveratrol (RSV) acts as a natural inhibitor of ETosis in NB4 cell lines.

·         RSV treatment led to a reduction in PAD4 expression and TNF-α cytokine levels.

·         Advanced research methods validated RSV’s therapeutic potential.

·         The study points to new pathways for improving APL treatment outcomes.

---

👩‍⚕️ About Dr. Minoo Shahidi

Dr. Shahidi is a distinguished Immunohematologist specializing in cancer, angiogenesis, and NETosis. She earned her PhD from Surrey University, UK, and currently serves as an Associate Professor at the Department of Hematology and Blood Banking, Iran University of Medical Sciences. Her extensive research has contributed significantly to the understanding of hematologic malignancies and inflammatory processes.

---

📅 Event Details

Event Name: International Conference on Cancer Science and Research

📍 Venue: Village Hotel Changi, 1 Netheravon Rd, Singapore 508502 & Online
🌐 Website: cancer.miconferences.com
📝 Abstract Submission: Submit Here
✅ Register Now: Click Here

📧 Email: cancer@mathewsconference.com
📞 Phone: +1 (312) 462-4448 | WhatsApp: +1 (424) 377 0967
🐦 Follow on X: @CancerWorldConf

---

#CancerConference2025 #APLResearch #ResveratrolStudy #NETosis #ETosis #OncologyInsights #HematologyUpdates #CancerWorldConf #DrMinooShahidi #CancerTreatment

Rethinking Cancer Theory: Dr. Chanda Siddoo-Atwal’s Groundbreaking Insights

The International Conference on Cancer Science and Research (November 17–19, 2025, Singapore & Online) will feature a thought-provoking oral virtual presentation by Dr. Chanda Siddoo-Atwal, President and Primary Biochemist of Moondust Cosmetics Ltd., Canada. Her talk, “Is Cancer Theory Incomplete?”, challenges long-standing assumptions in cancer biology and opens up a new perspective on carcinogenesis.

🌟 Key Takeaways from the Presentation

·         Traditional cancer theory, largely centered on DNA mutations, may not fully explain how all cancers develop.

·         Research shows that uncontrolled apoptosis (programmed cell death) can directly lead to tumor formation.

·         Animal and human studies suggest that increased apoptosis in tissues may accelerate cancer development.

·         Not all carcinogens are mutagens, pointing to alternate pathways in cancer initiation.

·         A proposed two-step apoptotic model highlights:

1.        Initial rise in apoptosis (from genetics, stress, or mutation).

2.        Development of apoptosis resistance, disrupting normal cell balance and fueling abnormal growth.

·         Early findings indicate these steps may be reversible with targeted apoptotic therapies, offering new hope for treatment.

👩‍🔬 About Dr. Chanda Siddoo-Atwal

Dr. Siddoo-Atwal earned her Ph.D. in Applied Sciences at Simon Fraser University, with research carried out at the BC Cancer Research Centre, followed by a post-doctoral fellowship at the Medical College of Wisconsin. With deep expertise in carcinogenesis and radiation-induced cancers, she has authored books, contributed to global oncology textbooks, and co-authored clinical texts. Through Moondust Cosmetics Ltd., she pioneers sunscreen research targeting apoptotic sunburn linked to skin cancer, bridging science with practical prevention.

📌 Event Information

·         Event Name: International Conference on Cancer Science and Research

·         Dates: November 17–19, 2025

·         Venue: Village Hotel Changi, Singapore & Online

·         🌐 Website: cancer.miconferences.com

·         📝 Register Here

·         📤 Submit Abstract

·         📩 Email: cancer@mathewsconference.com

·         📞 Phone: +1 (312) 462-4448 | WhatsApp: +1 (424) 377 0967

·         Follow updates on X: @CancerWorldConf

#CancerTheory #CancerScience2025 #Carcinogenesis #ApoptosisResearch #OncologyInnovation #CancerConference #CancerBiology #CancerTreatment #HybridConference #OncologyUpdates

Oncology Advances in Focus: Dr. Rainer Lipp’s Research on NSCLC

 We are pleased to share that Dr. Rainer Lipp, Co-founder of GermanOncology GmbH, Germany, will present his latest research at the International Conference on Cancer Science and Research, happening November 17–19, 2025, in Singapore & Online.

🩺 Presentation Title

General and age-dependent development of firstline (1L) therapies in patients with metastatic non-small cell lung cancer (NSCLC) from 2016–2024 in the standard care situation of oncological practices

📌 Key Highlights from the Study

• Data analyzed from 1,250 patients treated in 25 oncological practices across Germany (2016–2024).
• Median patient age: 68 years; with 76.8% ≤75 years and 23.2% >75 years.
• Over the last 8 years, a shift from chemotherapy to immunotherapy combinations was observed.
• ICI (Immune Checkpoint Inhibitor) use grew from 33.1% (2016–2019) to 79.9% (2022–2024).
• Traditional chemotherapy ± Bevacizumab declined from 58.4% to 13.6%.
• Patients >75 years were more frequently treated with ICI monotherapy (30.3%), while younger patients ≤75 years saw higher use of ICI combinations (59.6%).
• Findings highlight the age-dependent treatment trends shaping NSCLC standard care.

👨‍⚕️ About the Speaker

Dr. Rainer Lipp is a board-certified hematologist and medical oncologist, specializing in real-world standard care research in hematology and oncology. He has held positions at the Lung Clinic Großhansdorf, University Hospital Münster, and University Hospital Hamburg-Eppendorf.

As Co-founder of GermanOncology GmbH, he leads a network of 20+ oncology practices, building a database of 15,000+ longitudinal patient datasets. Dr. Lipp also manages non-interventional studies for pharmaceutical companies and supports healthcare consulting in hospital outpatient settings and reimbursement processes.

📅 Event Information

Event Name: International Conference on Cancer Science and Research
Dates: November 17–19, 2025
Venue: Village Hotel Changi, Singapore & Online

🌐 Event Website
📝 Register Here
✍️ Submit Abstract

📧 cancer@mathewsconference.com | 📞 +1 (312) 462-4448 | WhatsApp: +1 (424) 377 0967
Follow us on X for live updates.

---

#CancerScience2025 #OncologyResearch #LungCancer #NSCLC #Immunotherapy #CancerConference #MedicalOncology #CancerTreatment #CancerCare #OncologyUpdates

Advancing Cancer Science with Nanocomposites and RF Applications

 We are delighted to announce that Prof. Paulo César De Morais, Catholic University of Brasília, Brazil, will deliver a keynote talk at the International Conference on Cancer Science and Research, scheduled for November 17–19, 2025, in Singapore.

His keynote presentation, titled:
“Cell viability assays under radiofrequency application modulated by nanomaterials”
will explore cutting-edge research at the intersection of nanotechnology, oncology, and radiofrequency-based therapy.

🔬 Key Highlights of the Presentation:

·         Application of the Hill model to analyze BMD (Benchmark Dose), LD50 (Lethal Dose 50), cooperativity (E), and dissociation constant (K).

·         Insights into the synergistic effects of nanomaterials and radiofrequency (RF) in cancer treatment.

·         Discussion on nanocomposites such as Graphene Oxide (GO) functionalized with polyethyleneimine (PEI) and decorated with gold nanoparticles (GO-PEI-Au).

·         Findings from cell viability assays using tumor cell lines like LLC-WRC-256 and B16-F10.

·         Evidence that while nanocomposites remain biocompatible without RF, the application of RF enhances cancer cell toxicity by several orders of magnitude.

·         Future outlook on applying these results to tumor animal models for advanced cancer research.

👨‍🏫 About the Speaker:

Prof. Paulo César De Morais, PhD, is an Emeritus Professor of Physics at the University of Brasília and a CNPq-1A Research Fellow. With more than 13,500 citations, 500+ publications, and 16 patents, he is a leading figure in nanotechnology and cancer science. He has presented over 200 invited talks across 35 countries, making him a globally recognized expert in his field.

---

📅 Event Dates: November 17–19, 2025
📍 Venue: Village Hotel Changi, 1 Netheravon Rd, Singapore 508502
🔗 Website: https://cancer.miconferences.com/
✍️ Register Here: Click to Register
📩 Submit Abstract: Click to Submit

📞 Contact Us:
Email: cancer@mathewsconference.com | Phone: +1 (312) 462-4448 | WhatsApp: +1 (424) 377 0967

🌍 Follow Us:

·         Facebook

·         X (Twitter)

---

#CancerConference2025 #CancerResearch #CancerScience #Nanomaterials #RadiofrequencyTherapy #OncologyResearch #CancerWorldConf #MathewsConferences #SingaporeConference #CancerInnovation

Advancing Cancer Care: Stem Cell Therapy for Radiotherapy Complications

Featured Speaker: Dr. Alain Chapel, Institute of Radiological Protection and Nuclear Safety, France

Session Type: Oral Virtual Presentation

Topic: From experimental research to clinical trial in the treatment of complication of radiotherapy by stem cells

---

🌟 Why This Research Matters

Radiotherapy remains a cornerstone in cancer treatment, but nearly 5–10% of patients develop serious long-term side effects, especially after pelvic radiation. These complications often lack standardized treatment, making innovation in this area a pressing need. Dr. Alain Chapel and his team have been exploring mesenchymal stromal stem cell (MSC) therapy as a potential breakthrough solution.

---

🔍 Key Insights from the Study

·         Clinical Problem: Late adverse gastrointestinal and pelvic complications post-radiotherapy can be life-threatening.

·         Preclinical Evidence: Animal models demonstrated that systemic MSC injections significantly alleviated radiation-induced damage.

·         Phase I Clinical Trial Results:

o    Patients experienced reduction in diarrhea, pain, hemorrhage, and inflammation.

o    Fistulization process was halted in one patient with remission lasting over 3 years.

o    No toxicity observed, supporting a favorable safety profile.

·         Ongoing PRISME Trial (NCT02814864):

o    Involves 12 patients across 6 radiotherapy centers.

o    Each patient receives three MSC injections at weekly intervals.

o    Primary goal: measurable improvement on LENT SOMA scale for rectal bleeding or hematuria.

o    Secondary goals: reduced need for pain medication, fewer digestive issues, and better quality of life.

·         Future Outlook: A Phase III clinical trial is planned if current results confirm long-term efficacy.

---

👨‍🔬 About Dr. Alain Chapel

Dr. Alain Chapel, PhD, has dedicated more than 30 years to advancing cell and gene therapy for radiation-induced damage. His work bridges experimental models with real-world clinical applications. He has collaborated on groundbreaking compassionate trials demonstrating MSC therapy’s effectiveness in hematopoietic failure, radiodermatitis, and radiotherapy overdoses. His extensive contributions also include editorial roles in leading international journals and active participation in global research societies.

---

📢 Join the Conference

Be part of this global platform where cutting-edge cancer research meets clinical innovation.

Event: International Conference on Cancer Science and Research

📍 Venue: Village Hotel Changi, Singapore
📅 Dates: November 17–19, 2025
🌐 Website: cancer.miconferences.com
✉️ Email: cancer@mathewsconference.com
📞 Phone: +1 (312) 462-4448 | WhatsApp: +1 (424) 377 0967

👉 Register Now | Submit Abstract

---

#CancerScience2025 #StemCellResearch #RadiotherapyComplications #CancerTreatment #OncologyConference #MSCtherapy #CancerInnovation #CancerResearch